

2020

ISSN 2574-2817

Vol.5 No.3

Recent emerging gut microbiome management modalities in acute diarrhea in children: (a comparative study review of different probiotic strains) an update!

*Amr I. M. Hawal, ***Wafaa S. M. Hegab, **Said M. M. El Deib, *****Gehan I. Mohamed, ****Malak A. Alia, *Yara K. G. Osman.

Anglo-Arabian Health Care Group,UAE Royal NMC Hospital, UAE The National Egyptian Institute of Diabetes & Endocrine Diseases, Egypt Prime Health Care Group, Dubai, UAE Family Medicine, PHC,Saudi Arabia

Abstract

Introduction: Acute Diarrheal Diseases considered as the most common leading causes of children mortality all over the globe. Today, only 39 per cent of children with Diarrhea in developing countries receive the recommended treatment, and limited trend data suggest that there has been little progress since 2000, more than 386000 children dies in India only due to A. Diarrhea every year. An international commitment to tackle childhood Diarrhea in the 1970s and 1980s resulted in a major reduction in child deaths. This came about largely through the scaling up of oral rehydration therapy, coupled with programs to educate caregivers on its appropriate use.But these efforts lost momentum as the world turned its attention to other global emergencies.Our review aims to search &updates the Evidence-Based Review Articles that study the use of specific probiotic strains, namely Lactobacillus rhamnosus GG (LGG) and Saccharomyces boulardii, for the management of children with acute gastroenteritis (AGE) as an adjunct to rehydration therapy.

This Literature Review also aim to show us the role of different probiotics in the treatment of acute diarrhea in children.

"Probiotics may be an effective adjunct to the management of diarrhea".L. rhamnosus GG (LGG) significantly reduced duration of diarrhea, daily stool outputs, improved stool consistency and reduced no. of hospitalization and fever in children compared to other probiotics (B. clausii and S. boulardii) & ORS group as we will discuss now.

The guidelines recommend the use of the specific probiotic strains, namely Lactobacillus rhamnosus GG (LGG) and Saccharomyces boulardii, for the management of children with acute gastroenteritis (AGE) as an adjunct to rehydration therapy.

Discussion: The Efficacy of any probiotic is strain-dependent ;

Lactobacillus acidophilus strain is effective in IBS but not in AAD,Bifidobacterium bifidum reported that one strain (CIDCA5310) inhibited enterocyte invasion by Salmonella arizonae, whereas the other (CIDCA 537) had no effect, Lactobacillus rhamnosus GG (ATCC) help in treatment of Acute diarrhea, Persistent diarrhea, Rotavirus diarrhea, Gastroenteritis. AAD (Antibiotic Associated Diarrhea) Prevention & Treatment, Traveller's diarrhea, Nosocomial diarrhea,Irritable Bowel Syndrome (IBS),Abdominal pain, Crying etc., Ulcerative colitis, Necrotizing Enterocolitis (NEC) in pre-term infants, As an adjuvant to vaccines to stimulate immunity, Gastrointestinal infections & Respiratory Infections, L. Rhamnosus GG - Age group help in treatment of Acute infectious diarrhea, Antibiotic-associated diarrhea(AAD), Nosocomial diarrhea, Acute Gastroenteritis (AGE), Irritable bowel syndrome(IBS), Preventing infections, Allergic diseases, C. difficile diarrhea Pouchitis, Adjuvant therapy for H. pylori Eradication.

Proved Advantages & Clinical Benefits of LGG Probiotic Strains Use: Lactobacillus rhamnosus GG (ATCC 53103) has a safe history of use in since1990, Can even be given to a 24 hrs old neonate..!Clinically studied in various age group population starting from new born preterm infants to elderly population, Clinically studied at various dosage range starting (120mn CFU to 2000bnCFU/d).

Do probiotics work in Acute Infectious Diarrhea?



ISSN 2574-2817 Page | 19

Pediatrics & Health Research

Volume 5, Issue 3





Vol.5 No.3

63 trial, 8014 subjects, That study concluded that: Its use reduced the duration of diarrhea by around 25 hours, Risk of diarrhea be> 4 days by 59% &One fewer diarrheal stool on day 2 after the intervention.

Comparative clinical study;L. rhamnosus GG vs. B. clausii vs. S. boulardii :

BMJ

RESEARCH

Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations

Roberto Berni Canani, assistant professor of paediatrics,¹ Pia Cirillo, paediatrician,¹ Gianluca

Group	Treatment	Dosage (twice daily)
1	Control: Oral rehydration solution(ORS) (N=92)	-
2	Saccharomyces boulardii (N=91)	5 billion CFU/dose
3	Bacillus clausii (N=100)	1 billion CFU/dose
4	Enterococcus faecium (N=91)	0.075 CFU/dose
4	Lactobacillus rhamnosus GG (ATCC 53103) (N=100) (uncoated)	6 billion CFU/dose

This Study designed to compare the efficacy of 5 different preparations recommended to parents in the treatment of acute diarrhea in children.

Design: Prospective randomized controlled clinical trial,Study Arm: N=571 children (age 3-36 months).,Duration: 5 days.

That study concluded that The use of LrGG P. Strains;

Reduce in duration of diarrhea: LrGG group has shown highest & significant efficacy in terms of reducing duration of diarrhea compared to other probiotics & ORS group.


Reduce in daily stool outputs: LrGG group has shown significant reduction in terms of no. of stools per day on Day-2 compared to other probiotics & ORS group.

Improve in stool consistency: LrGG group has shown significant improvement in terms of stool consistency on Day-2 compared to other probiotics & ORS group.

Recent content analysis report of various probiotic brands: (Indian Pediatrics, April 2018 Issue ...) Comparative Study of 3 Brands, Enterogermina vs. Tufpro vs. DarolacAqua ;

ISSN 2574-2817

These figure that show us the study



That comparative review stated only product 1 was found to contain a homogenous population of bacillus clausiiwhere as product 2 and product 3 showed growth of bacillus subiilis species in the samples.

Conclusions: Our mini review aims to use of the specific probiotic strains, namely Lactobacillus rhamnosus GG (LGG) for the and Saccharomyces boulardii, management of children with acute gastroenteritis (AGE) as an adjunct to rehydration therapy. The aim of this Mini Review also is to show us the role of probiotic in the treatment of acute diarrhea in children. we review the evidence of several Probiotics modalities for AD treatment. We describe the Clinical Impact & prevalence of Acute Diarrhea in children and its complications, provide an overview of current treatments, and finally, discuss recent emergent Gut approaches to AD management. Specifically, we will describe - in a Comparative study - on the utility of different kinds of Probiotics known & used and common natural products in the treatment of Acute cases of AD and focus on recent, high-quality studies. Adverse effects and potential interactions of each therapy will be highlighted where applicable. Some probiotics agents have a Benifitiary effects on the onset, course of acute Diarrheal illnesses but still in need for further reviews on the side effects & safety of such agents.

Biography:

Dr. Said is a Pediatrician and Neonatologist whose experience in the field spans 15 years, backed by a higher education degree from royal college of pediatrics'and child health in UK,in addition to master degree from Ain Shams university in Egypt one of the oldest and top ranking universities in the MENA region. He is pioneering an open and contextual evaluation model based on constructive responses, which has led in the creation of new methods to improve pediatric healthcare, neonatology and pediatric nutrition. Dr.said has established



ISSN 2574-2817

2020

Vol.5 No.3

this model following his years of experiences in medical practice, research and evaluation, and teaching and administration in hospitals and medical universities in the reigion, including Egypt, kuwait and the UAE

<u>34th Global Summit On Pediatrics;</u> September 14-15, 2020.

Abstract Citation:

Said El deib,Recent emerging gut microbiome management modalities in acute diarrhea in children: (a comparative study review of different probiotic strains) an update!,Global Pediatrics Summit 2020, 34th Global Summit On Pediatrics; September 14-15, 2020.